Bretylium compounds are pharmaceutical agents, primarily used in the treatment of life-threatening ventricular arrhythmias, that work by stabilizing the cardiac membrane and inhibiting the release of norepinephrine from sympathetic nerve endings.
An agent that blocks the release of adrenergic transmitters and may have other actions. It was formerly used as an antihypertensive agent, but is now proposed as an anti-arrhythmic.
An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.
An indirect sympathomimetic. Tyramine does not directly activate adrenergic receptors, but it can serve as a substrate for adrenergic uptake systems and monoamine oxidase so it prolongs the actions of adrenergic transmitters. It also provokes transmitter release from adrenergic terminals. Tyramine may be a neurotransmitter in some invertebrate nervous systems.
Amidines are organic compounds containing the functional group consisting of a nitrogen atom connected to two carbon atoms by double bonds, with the remaining two bonds attached to hydrogen and any other organic substituent.
The study of the origin, nature, properties, and actions of drugs and their effects on living organisms.
An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
A nicotinic antagonist most commonly used as an experimental tool. It has been used as a ganglionic blocker in the treatment of hypertension but has largely been supplanted for that purpose by more specific drugs.
A nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.
Compounds containing the hexamethylenebis(trimethylammonium) cation. Members of this group frequently act as antihypertensive agents and selective ganglionic blocking agents.

Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat. (1/124)

We examined the effect of stress on colonic epithelial physiology, the role of corticotropin-releasing hormone (CRH), and the pathways involved. Rats were restrained or injected intraperitoneally with CRH or saline. Colonic segments were mounted in Ussing chambers, in which ion secretion and permeability (conductance and probe fluxes) were measured. To test the pathways involved in CRH-induced changes, rats were pretreated with hexamethonium, atropine, bretylium, doxantrazole, alpha-helical CRH-(9-41) (all intraperitoneally), or aminoglutethimide (subcutaneously). Restraint stress increased colonic ion secretion and permeability to ions, the bacterial peptide FMLP, and horseradish peroxidase (HRP). These changes were prevented by alpha-helical CRH-(9-41) and mimicked by CRH (50 microgram/kg). CRH-induced changes in ion secretion were abolished by alpha-helical CRH-(9-41), hexamethonium, atropine, or doxantrazole. CRH-stimulated conductance was significantly inhibited by alpha-helical CRH-(9-41), hexamethonium, bretylium, or doxantrazole. CRH-induced enhancement of HRP flux was significantly reduced by all drugs but aminoglutethimide. Peripheral CRH reproduced stress-induced colonic epithelial pathophysiology via cholinergic and adrenergic nerves and mast cells. Modulation of stress responses may be relevant to the management of colonic disorders.  (+info)

Preventing ventricular fibrillation by flattening cardiac restitution. (2/124)

Ventricular fibrillation is the leading cause of sudden cardiac death. In fibrillation, fragmented electrical waves meander erratically through the heart muscle, creating disordered and ineffective contraction. Theoretical and computer studies, as well as recent experimental evidence, have suggested that fibrillation is created and sustained by the property of restitution of the cardiac action potential duration (that is, its dependence on the previous diastolic interval). The restitution hypothesis states that steeply sloped restitution curves create unstable wave propagation that results in wave break, the event that is necessary for fibrillation. Here we present experimental evidence supporting this idea. In particular, we identify the action of the drug bretylium as a prototype for the future development of effective restitution-based antifibrillatory agents. We show that bretylium acts in accord with the restitution hypothesis: by flattening restitution curves, it prevents wave break and thus prevents fibrillation. It even converts existing fibrillation, either to a periodic state (ventricular tachycardia, which is much more easily controlled) or to quiescent healthy tissue.  (+info)

Effects of forearm bier block with bretylium on the hemodynamic and metabolic responses to handgrip. (3/124)

We tested the hypothesis that a reduction in sympathetic tone to exercising forearm muscle would increase blood flow, reduce muscle acidosis, and attenuate reflex responses. Subjects performed a progressive, four-stage rhythmic handgrip protocol before and after forearm bier block with bretylium as forearm blood flow (Doppler) and metabolic (venous effluent metabolite concentration and (31)P-NMR indexes) and autonomic reflex responses (heart rate, blood pressure, and sympathetic nerve traffic) were measured. Bretylium inhibits the release of norepinephrine at the neurovascular junction. Bier block increased blood flow as well as oxygen consumption in the exercising forearm (P < 0.03 and P < 0.02, respectively). However, despite this increase in flow, venous K(+) release and H(+) release were both increased during exercise (P < 0.002 for both indexes). Additionally, minimal muscle pH measured during the first minute of recovery with NMR was lower after bier block (6.41 +/- 0.08 vs. 6.20 +/- 0.06; P < 0.036, simple effects). Meanwhile, reflex effects were unaffected by the bretylium bier block. The results support the conclusion that sympathetic stimulation to muscle during exercise not only limits muscle blood flow but also appears to limit anaerobiosis and H(+) release, presumably through a preferential recruitment of oxidative fibers.  (+info)

Ciliary ganglion stimulation. II. Neurogenic, intraocular pathway for excitatory effects on aqueous humor production and outflow. (4/124)

Data obtained suggest that preganglionic stimulation of the ciliary ganglion produces an increase of aqueous humor formation and of facility of outflow "C" through the following neurogenic pathway: (1) the preganglionic fibers synapse in the ciliary ganglion as evidenced by depression of the response with nicotine applied topically to the ganglion. (2) The impulse proceeds to the equivalent of an intraocular interneuron which can be blocked by low concentrations of atropine and has been previously identified as being an E-2 receptor site. (3) From the interneuron, activity is ultimately exerted without further synapse on alpha-adrenergic receptors through the release of norepinephrine from the neuronal terminals. The adrenergic mechanism of action is supported by the inhibition of the responses by phenoxybenzamine, bretylium, and guanethidine. Constriction of efferent ciliary process blood vessels by neuron-released norepinephrine seems to be the end effect responsible for the increased production of aqueous humor. The site of the end response to increase "C" is unclear.  (+info)

Effect of destruction of the posterior pituitary on the diuresis from left atrial receptors. (5/124)

1. In anaesthetized dogs, stimulation of atrial receptors after destruction of the pituitary gland results in a diuresis. This response was not abolished by the administration of bretylium tosylate and was also observed in a surgically denervated kidney. 2. The diuresis is qualitatively similar to that observed in anaesthetized dogs with intact pituitary glands. 3. It is concluded that the diuresis which results from stimulation of the left atrial receptors is mediated by a blood-borne agent which is not the antidiuretic hormone.  (+info)

Acute cold exposure induces vagally mediated Fos expression in gastric myenteric neurons in conscious rats. (6/124)

Acute cold exposure-induced activation of gastric myenteric neurons in conscious rats was examined on longitudinal muscle-myenteric plexus whole mount preparations. Few Fos-immunoreactive (IR) cells (<1/ganglion) were observed in 24-h fasted rats semirestrained at room temperature. Cold exposure (4 degrees C) for 1-3 h induced a time-related increase of Fos-IR cells in corpus and antral myenteric ganglia with a maximal plateau response (17 +/- 3 and 18 +/- 3 cells/ganglion, respectively) occurring at 2 h. Gastric vagotomy partly prevented, whereas bilateral cervical vagotomy completely abolished, Fos expression in the myenteric cells induced by cold exposure (2 h). Hexamethonium (20 mg/kg) also prevented 3-h cold exposure-induced myenteric Fos expression by 76-80%, whereas atropine or bretylium had no effect. Double labeling revealed that cold (3 h)-induced Fos-IR myenteric cells were mainly neurons, including a substantial number of choline acetyltransferase-containing neurons and most NADPH-diaphorase-positive neurons. These results indicate that acute cold exposure activates cholinergic as well as nitrergic neurons in the gastric myenteric ganglia through vagal nicotinic pathways in conscious rats.  (+info)

Influence of cocaine and sodium on bretylium uptake by reserpine-treated guinea-pig left atrium. (7/124)

1 The effects of cocaine and sodium on bretylium uptake into sympathetic nerve terminals were investigated in the reserpine-treated guinea-pig left atrium. The ability of bretylium pretreatment to increase the retention of noradrenaline was used as an index of bretylium uptake. Such increased retention has been assessed both by direct measurement and by the ability of tyramine to produce an inotropic response. 2 The restoration of the response to tyramine after incubation with noradrenaline was abolished when the atrium was pretreated with bretylium in the presence of cocaine. When bretylium was added before cocaine, or when alpha-methyl-noradrenaline (not a substrate for monoamine oxidase) was used for incubation, the responses to tyramine were restored in the normal way. 3 Bretylium greatly enhanced the retention of [3-H]-noradrenaline; when bretylium was added in the presence of cocaine, [3-H]-noradrenaline retention was severely impaired. 4 Pretreatment with bretylium in a low-sodium (25 mM) or sodium-free medium significantly decreased the retention of [3-H]-noradrenaline, as compared with the control. 5 Potassium deprivation did not modify the enhanced retention of [3-H]-noradrenaline induced by bretylium pretreatment. 6 Bretylium was released from the nerve terminals by exposure of the preparation to a sodium-free medium or to a solution containing calcium 50 mM, leading to a considerable decrease in [3-H]-noradrenaline retention. 7 The results are consistent with the view that both cocaine and sodium deprivation block the uptake of bretylium by the adrenergic nerve terminals, and that bretylium is probably taken up by a mechanism similar to or identical with the uptake system for noradrenaline and other amines.  (+info)

Studies of uptake of the bretylium analogue, iodobenzyltrimethylammonium iodide, by non-primate, monkey and human hearts. (8/124)

Uptake of (+/-)-[3H]-noradrenaline, [14C]-bretylium and [125I]-o-iodobenzyltrimethylammonium iodide (RIBA) by rat heart was studied by the Langendorff technique. All three compounds showed significant uptake. 2 Corticosterone and 17-beta-oestradiol inhibited the uptake of all three compounds by rat heart, a finding consistent with extraneuronal uptake (uptake2). 3 [131I]-RIBA was injected intravenously into pigs and monkeys (M. speciosus). Myocardial samples taken from pigs killed 1 and 2 h after injection showed significant uptake. No significant uptake was found in myocardial samples of monkeys killed 10 min, 2 h and 24 h, respectively, after injection. 4 Four normal human volunteers received [125I]-RIBA intravenously and the image of the precordial area was followed by means of scintillation camera for the first 4 h after injection. In two of the subjects, the scintigrams were repeated at 22 and 23 h after injection, respectively. No evidence of myocardial uptake was observed. 5 These results suggest the possibility that man and at least one other primate species may differ from lower species with regard to uptake.  (+info)

Bretylium compounds are a class of medications that are primarily used in the management of life-threatening cardiac arrhythmias (abnormal heart rhythms). Bretylium tosylate is the most commonly used formulation. It works by stabilizing the membranes of certain types of heart cells, which can help to prevent or stop ventricular fibrillation and other dangerous arrhythmias.

Bretylium compounds are typically administered intravenously in a hospital setting under close medical supervision. They may be used in conjunction with other medications and treatments for the management of cardiac emergencies. It's important to note that bretylium compounds have a narrow therapeutic index, which means that the difference between an effective dose and a toxic one is relatively small. Therefore, they should only be administered by healthcare professionals who are experienced in their use.

Like all medications, bretylium compounds can cause side effects, including but not limited to:
- Increased heart rate
- Low blood pressure
- Nausea and vomiting
- Dizziness or lightheadedness
- Headache
- Tremors or muscle twitching
- Changes in mental status or behavior

Healthcare providers will monitor patients closely for any signs of adverse reactions while they are receiving bretylium compounds.

Bretylium tosylate is a medication that is used in the treatment of life-threatening cardiac arrhythmias (abnormal heart rhythms). It works by stabilizing the electrical activity of the heart and preventing irregular heartbeats. Bretylium tosylate is typically given intravenously in a hospital setting under the close supervision of a healthcare professional.

The chemical name for bretylium tosylate is N-[3-(dimethylamino)propyl]-N'-phenylmethanesulfonamidine and its molecular formula is C12H21N2O4S. It is a white, crystalline powder that is soluble in water and alcohol.

Bretylium tosylate has been used for many years as an antiarrhythmic drug, but its use has declined in recent years due to the availability of newer medications with fewer side effects. However, it may still be used in certain situations where other treatments have failed or are not appropriate.

It is important to note that bretylium tosylate should only be administered under the direction of a healthcare professional and should not be used without medical supervision. It can cause serious side effects, including low blood pressure, rapid heart rate, and irregular heart rhythms, and may interact with other medications.

Guanethidine is an antihypertensive medication that belongs to the class of drugs known as ganglionic blockers or autonomic nervous system (ANS) inhibitors. It works by blocking the action of certain chemicals (neurotransmitters) in the body, which results in decreased blood pressure and heart rate.

Guanethidine is not commonly used today due to its side effects and the availability of safer and more effective antihypertensive medications. Its medical definition can be stated as:

A synthetic antihypertensive agent that acts by depleting norepinephrine stores in postganglionic adrenergic neurons, thereby blocking their activity. Guanethidine is used primarily in the treatment of hypertension and occasionally in the management of sympathetic nervous system-mediated conditions such as essential tremor or neurogenic pain.

Sympatholytics are a class of drugs that block the action of the sympathetic nervous system, which is the part of the autonomic nervous system responsible for preparing the body for the "fight or flight" response. Sympatholytics achieve this effect by binding to and blocking alpha-adrenergic receptors or beta-adrenergic receptors located in various organs throughout the body, including the heart, blood vessels, lungs, gastrointestinal tract, and urinary system.

Examples of sympatholytic drugs include:

* Alpha blockers (e.g., prazosin, doxazosin)
* Beta blockers (e.g., propranolol, metoprolol)
* Centrally acting sympatholytics (e.g., clonidine, methyldopa)

Sympatholytics are used to treat a variety of medical conditions, including hypertension, angina, heart failure, arrhythmias, and certain neurological disorders. They may also be used to manage symptoms associated with anxiety or withdrawal from alcohol or other substances.

Tyramine is not a medical condition but a naturally occurring compound called a biogenic amine, which is formed from the amino acid tyrosine during the fermentation or decay of certain foods. Medically, tyramine is significant because it can interact with certain medications, particularly monoamine oxidase inhibitors (MAOIs), used to treat depression and other conditions.

The interaction between tyramine and MAOIs can lead to a hypertensive crisis, a rapid and severe increase in blood pressure, which can be life-threatening if not treated promptly. Therefore, individuals taking MAOIs are often advised to follow a low-tyramine diet, avoiding foods high in tyramine, such as aged cheeses, cured meats, fermented foods, and some types of beer and wine.

Amidines are organic compounds that contain a functional group with the structure R-C=N-R, where R can be an alkyl or aromatic group. This functional group consists of a carbonyl (C=O) group and a nitrogen atom (N) connected to two organic groups (R).

In medical terminology, amidines are not commonly used. However, some amidine derivatives have been investigated for their potential therapeutic properties. For example, certain amidine compounds have shown antimicrobial, anti-inflammatory, and antiviral activities. Some of these compounds have also been studied as potential drugs for the treatment of various diseases, including cancer, cardiovascular disease, and neurological disorders.

It is important to note that while some amidines may have therapeutic potential, they can also be toxic at high concentrations and should be handled with care.

Pharmacology is the branch of medicine and biology concerned with the study of drugs, their actions, and their uses. It involves understanding how drugs interact with biological systems to produce desired effects, as well as any adverse or unwanted effects. This includes studying the absorption, distribution, metabolism, and excretion of drugs (often referred to as ADME), the receptors and biochemical pathways that drugs affect, and the therapeutic benefits and risks of drug use. Pharmacologists may also be involved in the development and testing of new medications.

Reserpine is an alkaloid derived from the Rauwolfia serpentina plant, which has been used in traditional medicine for its sedative and hypotensive effects. In modern medicine, reserpine is primarily used to treat hypertension (high blood pressure) due to its ability to lower both systolic and diastolic blood pressure.

Reserpine works by depleting catecholamines, including norepinephrine, epinephrine, and dopamine, from nerve terminals in the sympathetic nervous system. This leads to a decrease in peripheral vascular resistance and heart rate, ultimately resulting in reduced blood pressure.

Reserpine is available in various forms, such as tablets or capsules, and is typically administered orally. Common side effects include nasal congestion, dizziness, sedation, and gastrointestinal disturbances like diarrhea and nausea. Long-term use of reserpine may also lead to depression in some individuals. Due to its potential for causing depression, other antihypertensive medications are often preferred over reserpine when possible.

I'm sorry for any confusion, but "Pempidine" does not appear to be a recognized term in medical terminology or pharmacology. It is possible that there may be a spelling error or typo in the term you are looking for. Please double-check the spelling and try again. If you meant "Pimobendan," I would be happy to provide information on that instead.

If you indeed meant "Pempidine," please let me know, and I will do my best to find more information about it.

Pentolinium tartrate is a synthetic anticholinergic drug, which is primarily used as a peripheral nerve blocker in surgical procedures. It functions by blocking the action of acetylcholine, a neurotransmitter that stimulates involuntary muscle contractions, secretions, and other physiological responses.

The tartrate form of pentolinium is a salt of pentolinium, which increases its solubility in water and facilitates its administration as an injection. The drug works by blocking the muscarinic acetylcholine receptors, particularly those found in smooth muscle, glands, and the heart.

Pentolinium tartrate is used to reduce salivation, sweating, and other autonomic responses during surgical procedures. It may also be used to treat conditions such as hypertension or urinary incontinence, although its use for these indications has declined with the development of newer drugs.

As with any medication, pentolinium tartrate can have side effects, including dry mouth, blurred vision, dizziness, and constipation. It should be used with caution in patients with certain medical conditions, such as glaucoma or prostatic hypertrophy, and should not be used in patients with a history of allergic reactions to the drug.

Hexamethonium compounds are a type of ganglionic blocker, which are medications that block the transmission of nerve impulses at the ganglia ( clusters of nerve cells) in the autonomic nervous system. These compounds contain hexamethonium as the active ingredient, which is a compound with the chemical formula C16H32N2O4.

Hexamethonium works by blocking the nicotinic acetylcholine receptors at the ganglia, which prevents the release of neurotransmitters and ultimately inhibits the transmission of nerve impulses. This can have various effects on the body, depending on which part of the autonomic nervous system is affected.

Hexamethonium compounds were once used to treat hypertension (high blood pressure), but they are rarely used today due to their numerous side effects and the availability of safer and more effective medications. Some of the side effects associated with hexamethonium include dry mouth, blurred vision, constipation, difficulty urinating, and dizziness upon standing.

... bephenium compounds MeSH D02.092.877.096.333 - bretylium compounds MeSH D02.092.877.096.333.150 - bretylium tosylate MeSH ... bretylium compounds MeSH D02.675.276.175.150 - bretylium tosylate MeSH D02.675.276.190 - cetrimonium compounds MeSH D02.675. ... trialkyltin compounds MeSH D02.691.850.900.910 - triethyltin compounds MeSH D02.691.850.900.950 - trimethyltin compounds MeSH ... mustard compounds MeSH D02.455.526.728.468 - mustard gas MeSH D02.455.526.728.650 - nitrogen mustard compounds MeSH D02.455. ...
Quaternary ammonium compounds). ... Bretylium (also bretylium tosylate) is an antiarrhythmic agent ... Bretylium should be used only in an ICU or emergency department setting and should not be used elsewhere due to its dramatic ... Bretylium will remain on the FDA's discontinued drug list since its withdrawal was not the result of a safety or effectiveness ... Many have cited these supply problems as an issue of raw materials needed in the production of Bretylium. By the release of the ...
Most agents of this class are guanidinium compounds and have little capacity to cross the blood-brain barrier. Lukas G (1973 ... Examples of these agents include bethanidine, bretylium, debrisoquine, guanadrel, guanazodine, guancydine, guanethidine, ... "Metabolism and biochemical pharmacology of guanethidine and related compounds". Drug Metab Rev. 2 (1): 101-16. doi:10.3109/ ...
Compounds that prolong the action potential: matching the modern classification, with the key drug example being amiodarone, ... Sympatholytic drugs (drugs blocking the effects of the sympathetic nervous system): examples included bretylium and adrenergic ... bretylium, amiodarone, ibutilide, sotalol, dofetilide, vernakalant, and dronedarone. Class IV agents are slow non- ...
Like other species in the genus, A. napellus contains several poisonous compounds, including enough cardiac poison that it was ... Other drugs used for ventricular arrhythmia include lidocaine, amiodarone, bretylium, flecainide, procainamide, and mexiletine ...
These are pharmaceutical drugs, naturally occurring compounds and other chemicals that influence the function of the ... Bethanidine Bretylium Guanadrel Guanazodine Guanclofine Guanethidine Guanoxan Oxidopamine (6-hydroxydopamine) Prischich, Davia ...
Bretylium Compounds* Actions. * Search in PubMed * Search in MeSH * Add to Search ... Actions of bretylium and guanethidine on the uptake and release of [3H]-noradrenaline. HERTTING G, AXELROD J, PATRICK RW. ... A new view of adrenergic nerve fibres, explaining the action of reserpine, bretylium, and guanethidine. BURN JH. BURN JH. Br ...
A 39-year-old woman with long QT interval syndrome received chronic oral bretylium tosylate during pregnancy and subsequent ... PubChem Compound (MeSH Keyword) LinkOut - more resources *. Full Text Sources. * Georg Thieme Verlag Stuttgart, New York ... Oral bretylium tosylate use during pregnancy and subsequent breastfeeding: a case report M Gutgesell 1 , E Overholt, R Boyle ... Oral bretylium tosylate use during pregnancy and subsequent breastfeeding: a case report M Gutgesell et al. Am J Perinatol. ...
... bephenium compounds MeSH D02.092.877.096.333 - bretylium compounds MeSH D02.092.877.096.333.150 - bretylium tosylate MeSH ... bretylium compounds MeSH D02.675.276.175.150 - bretylium tosylate MeSH D02.675.276.190 - cetrimonium compounds MeSH D02.675. ... trialkyltin compounds MeSH D02.691.850.900.910 - triethyltin compounds MeSH D02.691.850.900.950 - trimethyltin compounds MeSH ... mustard compounds MeSH D02.455.526.728.468 - mustard gas MeSH D02.455.526.728.650 - nitrogen mustard compounds MeSH D02.455. ...
Bretylium Compounds,N0000007589, Pyrimidinones,N0000007588, Pyrimidines,N0000007587, Biogenic Monoamines,N0000007586, Amino ... Magnesium Compounds,N0000007803, Iodine Compounds,N0000007802, Fluorine Compounds,N0000007801, Calcium Compounds,N0000007800, ... Heterocyclic Compounds with 4 or More Rings,N0000008261, Heterocyclic Compounds, 2-Ring,N0000008260, Heterocyclic Compounds, 1- ... Selenium Compounds,N0000007943, Silver Compounds,N0000007942, Lithium Compounds,N0000007941, Terpenes,N0000007940, Gallium, ...
Bretylium & Guanethidine: Two New Drugs Producing Specific Blockade of the Sympathetic Nervous System Digital Record ...
Bretylium Compounds D2.675.276.175 Bretylium Tosylate D2.675.276.175.150 Brimonidine Tartrate D3.438.857.70 D3.633.100.857.70 ... Heterocyclic Compounds with 4 or More Rings D3.549 D3.633.400 (Replaced for 2016 by Heterocyclic Compounds, 4 or More Rings) ... Bicyclo Compounds, Heterocyclic D2.455.426.100.80.85 D3.438.260 D4.75.80.875 (Replaced for 2016 by Bridged Bicyclo Compounds, ... Heterocyclic Compounds, 2-Ring D3.438 D3.633.100 Heterocyclic Compounds, 3-Ring D3.494 D3.633.300 Heterotrophic Processes ...
Bephenium Compounds [D02.092.877.096.166] * Bretylium Compounds [D02.092.877.096.333] * Bretylium Tosylate [D02.092.877.096. ... Benzylammonium compounds with the formula Br-phenyl-CN+R3 that include BRETYLIUM TOSYLATE.. Terms. Bretylium Compounds ... Benzylammonium compounds with the formula Br-phenyl-CN+R3 that include BRETYLIUM TOSYLATE.. Entry Version. BRETYLIUM CPDS. ... Bretylium Compounds Preferred Concept UI. M0002919. Registry Number. 0. Scope Note. ...
Bephenium Compounds [D02.092.877.096.166] * Bretylium Compounds [D02.092.877.096.333] * Bretylium Tosylate [D02.092.877.096. ... Benzylammonium compounds with the formula Br-phenyl-CN+R3 that include BRETYLIUM TOSYLATE.. Terms. Bretylium Compounds ... Benzylammonium compounds with the formula Br-phenyl-CN+R3 that include BRETYLIUM TOSYLATE.. Entry Version. BRETYLIUM CPDS. ... Bretylium Compounds Preferred Concept UI. M0002919. Registry Number. 0. Scope Note. ...
Bretylium Compounds - Preferred Concept UI. M0002919. Scope note. Benzylammonium compounds with the formula Br-phenyl-CN+R3 ... Benzylammonium compounds with the formula Br-phenyl-CN+R3 that include BRETYLIUM TOSYLATE.. ...
Bretylium Compounds1. *Clinical Trials as Topic1. *Depression1. *Diuretics1 ...
The British compound is bretylium tosylate (Darenthin®). The American drug is guanethidine (Ismelin®). Both agents seem to ... dine were announced a group of British investigators published their report that bretylium tosylate, a com- pound which is ... Clinical trials of bretylium first in England and then in this country indicated that the drug produced pre- dominantly a ... BRETYLIUM & GUANETHIDINE Two New Drugs Producing Specific Blockade of the Sympathetic Nervous System EDWARD D. FREIS, M.D. ...
Bretylium Compounds D2.675.276.175 Bretylium Tosylate D2.675.276.175.150 Brimonidine Tartrate D3.438.857.70 D3.633.100.857.70 ... Heterocyclic Compounds with 4 or More Rings D3.549 D3.633.400 (Replaced for 2016 by Heterocyclic Compounds, 4 or More Rings) ... Bicyclo Compounds, Heterocyclic D2.455.426.100.80.85 D3.438.260 D4.75.80.875 (Replaced for 2016 by Bridged Bicyclo Compounds, ... Heterocyclic Compounds, 2-Ring D3.438 D3.633.100 Heterocyclic Compounds, 3-Ring D3.494 D3.633.300 Heterotrophic Processes ...
Bretylium Compounds D2.675.276.175 Bretylium Tosylate D2.675.276.175.150 Brimonidine Tartrate D3.438.857.70 D3.633.100.857.70 ... Heterocyclic Compounds with 4 or More Rings D3.549 D3.633.400 (Replaced for 2016 by Heterocyclic Compounds, 4 or More Rings) ... Bicyclo Compounds, Heterocyclic D2.455.426.100.80.85 D3.438.260 D4.75.80.875 (Replaced for 2016 by Bridged Bicyclo Compounds, ... Heterocyclic Compounds, 2-Ring D3.438 D3.633.100 Heterocyclic Compounds, 3-Ring D3.494 D3.633.300 Heterotrophic Processes ...
Bretylium Compounds D2.675.276.175 Bretylium Tosylate D2.675.276.175.150 Brimonidine Tartrate D3.438.857.70 D3.633.100.857.70 ... Heterocyclic Compounds with 4 or More Rings D3.549 D3.633.400 (Replaced for 2016 by Heterocyclic Compounds, 4 or More Rings) ... Bicyclo Compounds, Heterocyclic D2.455.426.100.80.85 D3.438.260 D4.75.80.875 (Replaced for 2016 by Bridged Bicyclo Compounds, ... Heterocyclic Compounds, 2-Ring D3.438 D3.633.100 Heterocyclic Compounds, 3-Ring D3.494 D3.633.300 Heterotrophic Processes ...
Bretylium Compounds D2.675.276.175 Bretylium Tosylate D2.675.276.175.150 Brimonidine Tartrate D3.438.857.70 D3.633.100.857.70 ... Heterocyclic Compounds with 4 or More Rings D3.549 D3.633.400 (Replaced for 2016 by Heterocyclic Compounds, 4 or More Rings) ... Bicyclo Compounds, Heterocyclic D2.455.426.100.80.85 D3.438.260 D4.75.80.875 (Replaced for 2016 by Bridged Bicyclo Compounds, ... Heterocyclic Compounds, 2-Ring D3.438 D3.633.100 Heterocyclic Compounds, 3-Ring D3.494 D3.633.300 Heterotrophic Processes ...
C13.371.270.750.249 Bretylium Compounds D2.92.102.175 D2.92.877.96.333 Bretylium Tosylate D2.92.102.175.150 D2.92.877.96. ... D3.383.946.276 Ammonium Compounds D2.92.102 D2.92.877 (Replaced for 2006 by Quaternary Ammonium Compounds) Ammotherapy E2.831. ... D2.886.706.537 Methonium Compounds D2.92.102.558 D2.92.877.250 (Replaced for 2006 by Bis-Trimethylammonium Compounds) ... Cetrimonium Compounds D2.92.102.190 D2.92.877.883.111 Chalcone D3.830.219.266.450.221.500 Chalcones D3.830.219.266.450.221 ...
Bretylium Compounds. Genre(s):. Archival Materials. Articles. Abstract:. In this brief article, intended to acquaint practicing ... Bretylium & Guanethidine: Two New Drugs Producing Specific Blockade of the Sympathetic Nervous System. Contributor(s):. The ... physicians with several new ganglionic blocking agents, Freis provided an overview of how bretylium tosylate and guanethidine ...
Drug Interactions: 1) Other antidysrhythmic drugs may exacerbate prolonged QT interval; 2) Antihypertensive agents may compound ... Incompatibilities with intravenous infusion include bretylium, esmolol, ethacrynate, milrinone, and amrinone. * Check apical ...
Bethanechol Compounds. *Bis-Trimethylammonium Compounds. *Bretylium Compounds. *Cetrimonium Compounds. *Chlorisondamine. * ... A naturally occurring compound that has been of interest for its role in osmoregulation. As a drug, betaine hydrochloride has ... Novel Natural Compounds and Their Anatomical Distribution in the Stinging Fireworm Hermodice carunculata (Annelida). Mar Drugs ...
Metabolized by hepatic conjugation to inactive compound. Elimination. Half-life: 40 min (initial); 24-72 hr (after 10-day ... Y-site: Amikacin, amphotericin B, atracurium, bretylium, calcium chloride, ceftazidime (?), ciprofloxacin, cisatracurium, ...
Int J Pharm Compound 2021 ;25,1:52-61. 4603. Journal. Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, ... Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives.. Am J Hosp Pharm ... Int J Pharm Compound 2001 ; 5: 314-321.. 1703. Journal. Schuster F, Bernard R.. Kompatibilität von enalaprilat i.v. mit ... Int J Pharm Compound 2006 ; 10: 230-232.. 2109. Journal. Pelletier E, Forest JM, Hildgen P.. Compatibilité de la kétamine ...
Product containing bretylium (medicinal product). Code System Preferred Concept Name. Product containing bretylium (medicinal ... Product containing bretylium (medicinal product) {56230001 , SNOMED-CT } Parent/Child (Relationship Type) Product containing ... bretylium in parenteral dose form (medicinal product form) {772355001 , SNOMED-CT } Product containing only bretylium ( ... Product containing quaternary ammonium compound (product) {765420008 , SNOMED-CT } Download Relationships Other Relationships ...
Dysrhythmias unresponsive to sodium bicarbonate therapy/ hyperventilation may respond to lidocaine, bretylium, or phenytoin. ... Phospholipidosis and testicular changes, commonly associated with tricyclic compounds, have been observed with Clomipramine ... CMIs lethality in overdose is considered to be similar to that reported for closely related tricyclic compounds marketed as ...
DARVON COMPOUND 08535 DDAVP 08540 DDS COMPOUND 08565 DEBROX 08585 DECADRON 08605 DECADRON-LA 08625 DECASPRAY 08660 DECONAMINE ... BRETYLIUM TOSYLATE 60250 BSS OPHTHALMIC 60265 BUPRENEX 60270 BUSPAR 60290 CAPOZIDE 60295 CEFOTAN 60325 CITRUCEL 60335 ... SOMA COMPOUND 28820 SOMA COMPOUND W/CODEINE 28825 SOMA 28833 SOMINEX 28910 SORBITOL 28920 SORBITRATE 29078 SPECTROBID 29250 ... COMPOUND W 07480 COMTREX 07500 CONCEPTROL 07543 CONJUGATED ESTROGENS 07545 CONRAY 07560 CONTAC 07565 CONTAC JR. 07640 CORACIN ...
The molecular formula of the compound is C19H21NO•HCl having a molecular weight of 316. It is a white crystalline solid readily ... Dysrhythmias unresponsive to sodium bicarbonate therapy/hyperventilation may respond to lidocaine, bretylium or phenytoin. Type ... At clinical dosages up to 150 mg per day, SINEQUAN can be given to man concomitantly with guanethidine and related compounds ... Characteristic of this type of compound, SINEQUAN has not been demonstrated to produce the physical tolerance or psychological ...
If true, this finding would compound the health disparity observed among those with limited English proficiency. This topic is ... Drugs bretylium * 2010betapace-af-sotalol-342365. Drugs sotalol * 2002900226-overview. Diseases & Conditions Pediatric ...
Klerman GL, Cole JO: Clinical pharmacology of imipramine and related antidepressant compounds. Int J Psychiatry 1976;3:267-304. ... Dysrhythmias unresponsive to sodium bicarbonate therapy/hyperventilation may respond to lidocaine, bretylium or phenytoin. Type ... Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram ... It is a white, odorless, crystalline compound which is freely soluble in water. ...
Benzothiadiazine Compounds, Rauwolfia and Hydralazine Creator: Freis, Edward D. Date: 22 March 1962 Publisher: Massachusetts ... Bretylium & Guanethidine: Two New Drugs Producing Specific Blockade of the Sympathetic Nervous System ...
  • This graph shows the total number of publications written about "Tetraethylammonium Compounds" by people in UAMS Profiles by year, and whether "Tetraethylammonium Compounds" was a major or minor topic of these publications. (uams.edu)
  • Below are the most recent publications written about "Tetraethylammonium Compounds" by people in Profiles over the past ten years. (uams.edu)
  • Below are the most recent publications written about "Benzalkonium Compounds" by people in Profiles. (jefferson.edu)
  • A new view of adrenergic nerve fibres, explaining the action of reserpine, bretylium, and guanethidine. (nih.gov)
  • Actions of bretylium and guanethidine on the uptake and release of [3H]-noradrenaline. (nih.gov)
  • BRETYLIUM & GUANETHIDINE Two New Drugs Producing Specific Blockade of the Sympathetic Nervous System EDWARD D. FREIS, M.D. Senior Medical Investigator, Veterans Administra- tion Hospital, Washington, D.C. The purpose of this communication is to acquaint practicing physicians with a new class of antihyper- tensive agents. (nih.gov)
  • Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy. (nih.gov)
  • Clinical trials of bretylium first in England and then in this country indicated that the drug produced pre- dominantly a postural hypotension and that it was free of the side effects of parasympathetic blockade. (nih.gov)
  • They represent, in truth, a new 88 class of compounds whose blocking effects seem to be limited to transmission of sympathetic nerve impulses. (nih.gov)
  • SINEQUAN® (doxepin hydrochloride) is one of a class of psychotherapeutic agents known as dibenzoxepin tricyclic compounds. (rxlist.com)
  • embryo media was then replaced with new embryo media (to mimic the procedure used for test compounds), and a second locomotion response was obtained. (eneuro.org)
  • These effects were antagonized by bretylium, a compound which blocks release of nore-pinephrine. (erowid.org)
  • Clarithromycin is first metabolized to 14-OH clarithromycin, which is active and works synergistically with its parent compound. (illumina.com)
  • It is a white, odorless, crystalline compound which is freely soluble in water. (nih.gov)